HomeCompareKTYCF vs JNJ

KTYCF vs JNJ: Dividend Comparison 2026

KTYCF yields 19.05% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KTYCF wins by $48.8K in total portfolio value
10 years
KTYCF
KTYCF
● Live price
19.05%
Share price
$10.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$68.9K
Annual income
$6,079.53
Full KTYCF calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — KTYCF vs JNJ

📍 KTYCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKTYCFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KTYCF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KTYCF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KTYCF
Annual income on $10K today (after 15% tax)
$1,619.05/yr
After 10yr DRIP, annual income (after tax)
$5,167.60/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, KTYCF beats the other by $4,463.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KTYCF + JNJ for your $10,000?

KTYCF: 50%JNJ: 50%
100% JNJ50/50100% KTYCF
Portfolio after 10yr
$44.4K
Annual income
$3,453.66/yr
Blended yield
7.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

KTYCF
No analyst data
Altman Z
7.6
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KTYCF buys
0
JNJ buys
0
No recent congressional trades found for KTYCF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKTYCFJNJ
Forward yield19.05%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$68.9K$20.0K
Annual income after 10y$6,079.53$827.78
Total dividends collected$38.2K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KTYCF vs JNJ ($10,000, DRIP)

YearKTYCF PortfolioKTYCF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$12,605$1,904.76$10,676$355.77+$1.9KKTYCF
2$15,731$2,243.84$11,407$389.39+$4.3KKTYCF
3$19,449$2,617.14$12,198$426.53+$7.3KKTYCF
4$23,835$3,024.07$13,056$467.62+$10.8KKTYCF
5$28,967$3,463.51$13,987$513.12+$15.0KKTYCF
6$34,928$3,933.88$14,998$563.56+$19.9KKTYCF
7$41,806$4,433.18$16,098$619.52+$25.7KKTYCF
8$49,692$4,959.03$17,295$681.69+$32.4KKTYCF
9$58,679$5,508.79$18,599$750.82+$40.1KKTYCF
10$68,866$6,079.53$20,022$827.78+$48.8KKTYCF

KTYCF vs JNJ: Complete Analysis 2026

KTYCFStock

Kits Eyecare Ltd. operates a digital eyecare platform for eyes in the United States and Canada. The company manufactures progressive and contact lenses, eyeglasses, and frames under the KITS brand, as well as distributes eyewear products of various brands. It operates through a network of optical e-commerce websites, including KITS.com, KITS.ca, OptiContacts.com, and ContactsExpress.ca. The company was incorporated in 2018 and is headquartered in Vancouver, Canada.

Full KTYCF Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this KTYCF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KTYCF vs SCHDKTYCF vs JEPIKTYCF vs OKTYCF vs KOKTYCF vs MAINKTYCF vs ABBVKTYCF vs MRKKTYCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.